- •November 16, 2002
- •February 14, 2003
- •February 21
- •February 28
- •March 7
- •March 10
- •March 12
- •March 14
- •March 15
- •March 17
- •March 19
- •March 21
- •March 24
- •March 26
- •March 28
- •March 30
- •March 31
- •April 2
- •April 2
- •April 8-10
- •April 12
- •April 16
- •April 20
- •April 20
- •April 23
- •April 25
- •April 27
- •April 29
- •June 6
- •June 13
- •June 17
- •June 21
- •June 23
- •June 24
- •July 2
- •July 5
- •August 14
- •September 8
- •September 24
- •References
- •Virology
- •Discovery of the SARS Virus
- •Initial Research
- •The Breakthrough
- •Coronaviridae
- •SARS Co-V
- •Genome Sequence
- •Morphology
- •Organization
- •Detection
- •Stability and Resistance
- •Natural Host
- •Antiviral Agents and Vaccines
- •Antiviral Drugs
- •Vaccines
- •Outlook
- •References
- •Routes of Transmission
- •Factors Influencing Transmission
- •Patient Factors in Transmission
- •Asymptomatic Patients
- •Symptomatic Patients
- •Superspreaders
- •The Unsuspected Patients
- •High-Risk Activities
- •Transmission during Quarantine
- •Transmission after Recovery
- •Animal Reservoirs
- •Conclusion
- •References
- •Introduction
- •Modeling the Epidemic
- •Starting Point
- •Global Spread
- •Hong Kong
- •Vietnam
- •Toronto
- •Singapore, February 2003
- •China
- •Taiwan
- •Other Countries
- •Eradication
- •Outlook
- •References
- •Introduction
- •International Coordination
- •Advice to travelers
- •Management of SARS in the post-outbreak period
- •National Measures
- •Legislation
- •Extended Case Definition
- •Quarantine
- •Reduce travel between districts
- •Quarantine after Discharge
- •Infection Control in Healthcare Settings
- •General Measures
- •Protective Measures
- •Hand washing
- •Gloves
- •Face Masks
- •Additional protection
- •Getting undressed
- •Special Settings
- •Intensive Care Units
- •Intubating a SARS Patient
- •Anesthesia
- •Triage
- •Internet Sources
- •Additional information
- •Infection Control in Households
- •Possible Transmission from Animals
- •After the Outbreak
- •Conclusion
- •References
- •Case Definition
- •WHO Case Definition
- •Suspect case
- •Probable case
- •Exclusion criteria
- •Reclassification of cases
- •CDC Case Definition
- •Diagnostic Tests
- •Introduction
- •Laboratory tests
- •Molecular tests
- •Virus isolation
- •Antibody detection
- •Interpretation
- •Limitations
- •Biosafety considerations
- •Outlook
- •Table, Figures
- •References
- •Clinical Presentation and Diagnosis
- •Clinical Presentation
- •Hematological Manifestations
- •Atypical Presentation
- •Chest Radiographic Abnormalities
- •Chest Radiographs
- •CT Scans
- •Diagnosis
- •Clinical Course
- •Viral Load and Immunopathological Damage
- •Histopathology
- •Lung Biopsy
- •Postmortem Findings
- •Discharge and Follow-up
- •Psychosocial Issues
- •References
- •Appendix: Guidelines
- •WHO: Management of Severe Acute Respiratory Syndrome (SARS)
- •Management of Suspect and Probable SARS Cases
- •Definition of a SARS Contact
- •Management of Contacts of Probable SARS Cases
- •Management of Contacts of Suspect SARS Cases
- •SARS Treatment
- •Antibiotic therapy
- •Antiviral therapy
- •Ribavirin
- •Neuraminidase inhibitor
- •Protease inhibitor
- •Human interferons
- •Human immunoglobulins
- •Alternative medicine
- •Immunomodulatory therapy
- •Corticosteroids
- •Other immunomodulators
- •Assisted ventilation
- •Non-invasive ventilation
- •Invasive mechanical ventilation
- •Clinical outcomes
- •Outlook
- •Appendix 1
- •A standardized treatment protocol for adult SARS in Hong Kong
- •Appendix 2
- •A treatment regimen for SARS in Guangzhou, China
- •References
- •Pediatric SARS
- •Clinical Manifestation
- •Radiologic Features
- •Treatment
- •Clinical Course
- •References
Laboratory tests 115
Negative PCR results do not exclude SARS. Besides the possibility of obtaining incorrect, false-negative test results (e.g. through lack of sensitivity), specimens may not have been collected at a time when the virus or its genetic material was present.
Currently, efforts are underway to improve the sensitivity of PCR assays to increase their clinical usefulness. One approach is to amplify another gene of SARS-CoV than the hitherto used polymerase gene; due to the unique transcription strategy of coronaviruses, a PCR targeting the nucleoprotein may have a higher sensitivity (Lai). While evaluations of such a PCR are ongoing, the protocol is already available from the Bernhard Nocht Institute.
Virus isolation
The presence of the infectious virus can be detected by inoculating suitable cell cultures (e.g., Vero cells) with patient specimens (such as respiratory secretions, blood or stool) and propagating the virus in vitro. Once isolated, the virus must be identified as SARS-CoV using further tests. Cell culture is a very demanding test, but currently (with the exception of animal trials) the only means to show the existence of a live virus. It has to be performed under at least biosafety safety level (BSL) 3 conditions (see below). Positive cell culture results indicate the presence of live SARS-CoV in the sample tested. Negative cell culture results do not exclude SARS (see negative PCR test result).
Antibody detection
Various methods provide a means for the detection of antibodies produced in response to infection with SARS-CoV. Different types of antibodies (IgM and IgG) appear and change in level during the course of infection. They can be undetectable in the early stages of infection. IgG usually remains detectable after resolution of the illness (Li).
The following test formats are being developed:
– Enzyme-linked immunosorbent assay (ELISA): a test which detects a mixture of IgM and IgG antibodies in the serum of SARS patients and reliably yields positive results at around day 21 after the onset of illness.
Kamps and Hoffmann (eds.)